Back to results
US 2023/0066798 A1Published application
Compositions and methods for post-operative ocular care
AssigneeOcular Science, Inc.
InventorsAnthony Sampietro, Damien Goldberg, Amy Frost, Brian Holdorf, Francis Mah
Life of this patent
Estimating the term…
Abstract
Provided herein are certain preservative-free ophthalmic formulations for post-operative ocular care.
Claims21
1-19. (canceled)
A method for treating an ocular condition of an eye, comprising administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen, wherein:
- the pharmaceutical composition comprises:
- (a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.045% to 0.055% of difluprednate,
- (b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.45% to 0.55% of moxifloxacin, and
- (c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.0675% to 0.0825% of bromfenac;
- wherein these percentages are with respect to weight per volume;
- the pharmaceutical composition is free of preservatives;
- and
- the ocular condition is care after cataract surgery, care after LASIK surgery, care for a retina of the eye after cataract surgery, care for a retina of the eye after retina surgery, in preparation for an intraocular procedure, or during the intraocular procedure.
5 more elements
A method for treating an ocular condition of an eye, comprising administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen;
- wherein
- the pharmaceutical composition comprises the following active pharmaceutical ingredients:
- (a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.045% to 0.055% of difluprednate,
- (b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.45% to 0.55% of moxifloxacin, and
- (c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.0675% to 0.0825% of bromfenac;
- wherein these percentages are with respect to weight per volume;
- the pharmaceutical composition is free of preservatives;
- at least two of the active pharmaceutical ingredients are compounded and stored in communication with each other;
- and
- the method is more effective as compared to a preexisting method, wherein the preexisting method administers the at least two active pharmaceutical ingredients from at least two separate and different containers.
7 more elements
Dependencies are inferred from the claim text.